The German group’s decision to switch focus to innate immunity had been on the cards since a deal with Roche last August.
After completing a phase I study Astrazeneca discontinues development of the Ionis-partnered AZD4785.
At a time when most of biotech seems to want to become “the next Genentech” Array Biopharma has stuck to a partnering model and, in hindsight, lost out in the process.
Day three of the biotech dog and pony show saw one pharma company that unequivocally wants and needs to buy.
The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
The company's stock slumped on disappointing data from its sitravatinib-Opdivo combo lung cancer study, and on news that the group will will need to carry out a…
Turbulence in Japan made the country’s biopharma industry a relatively safe haven – but clinical success or setbacks dictated the fortunes of most mid and small-cap…